Protagonist Therapeutics (PTGX) Stock Price
Protagonist Therapeutics Price
Over the last 8 years Protagonist Therapeutics grew revenue by 10.9% annually, reaching 46.02 M USD. For Protagonist Therapeutics, the net margin of -282.8% is up versus -458.9% a few years ago. The consensus 12-month price target for Protagonist Therapeutics is 170.00 USD, about 24.5% above where the stock trades today. Of 20 analysts, 19 rate the stock a buy — an overall Buy consensus.
Protagonist Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Protagonist Therapeutics business model & stock analysis
Frequently asked questions about Protagonist Therapeutics
The business model of Protagonist Therapeutics Inc revolves around developing and commercializing peptide-based drugs for the treatment of gastrointestinal diseases and disorders. Protagonist Therapeutics Inc focuses on discovering and designing potential drug candidates to target certain biological pathways and address unmet medical needs. By leveraging its proprietary technology platform, the company aims to advance innovative therapies that have the potential to improve outcomes for patients suffering from various gastrointestinal conditions. With a strong focus on research and development, Protagonist Therapeutics Inc aims to bring novel treatments to market that can positively impact the lives of those affected by gastrointestinal diseases.
Protagonist Therapeutics Inc is primarily active in the pharmaceutical industry.
The main competitors of Protagonist Therapeutics Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Pfizer Inc, and Roche Holding AG.
Protagonist Therapeutics Inc. is a biopharmaceutical company specializing in the development of peptide-based drugs. Founded in 2006, the company is headquartered in Newark, California. Protagonist Therapeutics Inc. focuses on discovering and developing novel therapeutics for the treatment of various diseases, including inflammatory bowel disease (IBD), gastrointestinal (GI) disorders, and other serious conditions. The company utilizes its proprietary peptide technology platform to design and optimize peptide drugs, aiming to provide targeted and effective treatments for patients in need. With a strong commitment to innovation and clinical research, Protagonist Therapeutics Inc. continues to strive towards advancing the field of peptide-based therapeutics for improved patient outcomes.
Protagonist Therapeutics Inc has achieved several significant milestones in its journey. The company successfully completed Phase 2 clinical trials for its potential drug PTG-100, which showed promising results in treating ulcerative colitis. Additionally, Protagonist Therapeutics Inc entered a partnership with Janssen Biotech to develop and commercialize PTG-200 for the treatment of Crohn's disease. Moreover, the company received Fast Track designation from the U.S. FDA for PTG-200, highlighting its potential in addressing unmet medical needs. Protagonist Therapeutics Inc's dedication to advancing novel therapeutic options marks a commendable achievement in the field of biotechnology.
Protagonist Therapeutics Inc is primarily present in the United States.
Protagonist Therapeutics Inc is a biopharmaceutical company that is driven by a strong set of values and corporate philosophy. They are committed to discovering and developing innovative peptide-based therapeutics that have the potential to transform patients' lives. With a focus on developing first-in-class oral peptide drugs, Protagonist Therapeutics Inc strives to provide novel treatment options for patients suffering from serious diseases. Their corporate philosophy revolves around collaboration, innovation, and scientific excellence, aiming to deliver value to patients, healthcare providers, and stakeholders. By combining cutting-edge research and an unwavering dedication to patient-centered solutions, Protagonist Therapeutics Inc embodies a commitment to advancing healthcare.
Analysts currently set an average price target of 163.71 USD for the Protagonist Therapeutics stock (median: 170.00 USD), implying +24.4 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Protagonist Therapeutics stock: 19 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Protagonist Therapeutics to generate revenue of 543.43 M USD and earnings per share of 4.67 USD.
Converted at the current exchange rate, the Protagonist Therapeutics share trades at 121.75 EUR (136.55 USD).
The Protagonist Therapeutics share (PTGX) is listed on 1 stock exchanges, including: NASDAQ (PTGX).
Protagonist Therapeutics Inc. is a biotechnology company specializing in the development of peptide therapeutics for the treatment of diseases. The company's business model aims to promote the research and development of peptide drugs through novel approaches such as proteolysis to achieve higher effectiveness for patients.
The expected revenue of Protagonist Therapeutics is 543.43 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Protagonist Therapeutics is 296.90 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Protagonist Therapeutics is currently 29.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Protagonist Therapeutics stock.
The price-to-sales ratio (P/S) of Protagonist Therapeutics is currently 15.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Protagonist Therapeutics stock.
The Eulerpool Quality Score for Protagonist Therapeutics is 3/10.
The ISIN of Protagonist Therapeutics is US74366E1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Protagonist Therapeutics is A2AP32. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Protagonist Therapeutics is PTGX. The ticker symbol is used to trade Protagonist Therapeutics shares on the stock exchange.
Protagonist Therapeutics stock
Protagonist Therapeutics Peer Group
Protagonist Therapeutics Ticker
Protagonist Therapeutics FIGI
All fundamentals and in-depth analysis of Protagonist Therapeutics
Our stock analysis for Protagonist Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protagonist Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.